HSCA Comments on FDA Bulk Substance Guidance
On behalf of the Healthcare Supply Chain Association (HSCA), we appreciate the opportunity to provide comments on the U.S. Food and Drug Administration (FDA) draft guidance on the use of bulk substances under Section 503B of the Federal Food, Drug, and Cosmetic Act. HSCA represents the nation’s leading healthcare group purchasing organizations (GPOs), the sourcing and purchasing partners to virtually all of America’s 7,000+ hospitals.
Related Posts
HSCA Comments on FDA Bulk Substance Guidance
May 25, 2018
On behalf of the Healthcare Supply Chain Association (HSCA), we appreciate the...
HSCA Announces Healthcare Cybersecurity Key Considerations
April 17, 2018
The Healthcare Supply Chain Association (HSCA) today announced the release of key...
Comments of the Healthcare Supply Chain Association (HSCA) on Supported Lifetimes and Legacy Medical Devices
May 31, 2018
Advances in information technology and medical devices, and increasing...
HSCA Applauds Senate Judiciary Committee for Advancing the CREATES Act
June 15, 2018
Washington, DC (June 14, 2018) – Healthcare Supply Chain Association (HSCA)...